Valuation: Gilead Sciences, Inc.

Capitalization 171B 145B 133B 126B 234B 15,808B 238B 1,560B 612B 7,663B 641B 628B 27,008B P/E ratio 2026 *
18.8x
P/E ratio 2027 * 17.1x
Enterprise value 177B 150B 138B 130B 241B 16,337B 246B 1,612B 632B 7,919B 662B 648B 27,911B EV / Sales 2026 *
5.85x
EV / Sales 2027 * 5.27x
Free-Float
99.9%
Yield 2026 *
2.39%
Yield 2027 * 2.44%

Last Transcript: Gilead Sciences, Inc.

1 day-0.66%
1 week-0.97%
Current month-1.24%
1 month-2.58%
3 months+10.19%
6 months+12.08%
Current year+12.14%
1 week 136.69
Extreme 136.69
141.4
1 month 133.89
Extreme 133.89
142.97
Current year 116.88
Extreme 116.88
157.29
1 year 93.37
Extreme 93.37
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 60 2019-02-28
Director of Finance/CFO 56 2019-10-31
Chief Tech/Sci/R&D Officer 64 2025-01-01
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Change 5d. change 1-year change 3-years change Capi.($)
-0.66%-0.97%+31.66%+64.29% 171B
+2.55%-1.32%+10.37%+150.61% 830B
-0.15%-1.79%+48.71%+45.44% 564B
-0.29%+0.21%+20.46%+30.57% 369B
+2.07%+1.39%+25.20%+15.80% 328B
+1.72%-0.74%+49.33%+25.56% 318B
+3.13%-1.94%+52.65%+3.69% 294B
+1.19%-2.41%+31.10%+35.44% 291B
+1.69%+1.22%+28.13%+44.38% 192B
+1.24%+8.21%-38.18%-54.92% 182B
Average +1.25%+0.03%+25.94%+36.09% 353.84B
Weighted average by Cap. +1.37%-0.64%+27.11%+55.40%

Financials

2026 *2027 *
Net sales 30.2B 25.58B 23.54B 22.28B 41.29B 2,795B 42.01B 276B 108B 1,355B 113B 111B 4,775B 32.05B 27.15B 24.98B 23.64B 43.82B 2,966B 44.59B 293B 115B 1,438B 120B 118B 5,067B
Net income 8.62B 7.3B 6.72B 6.36B 11.78B 797B 11.99B 78.65B 30.84B 386B 32.32B 31.65B 1,362B 10B 8.47B 7.8B 7.38B 13.68B 926B 13.92B 91.32B 35.81B 449B 37.53B 36.75B 1,582B
Net Debt 5.71B 4.84B 4.45B 4.21B 7.81B 528B 7.95B 52.14B 20.44B 256B 21.42B 20.98B 903B -1.94B -1.64B -1.51B -1.43B -2.65B -179B -2.7B -17.69B -6.94B -86.92B -7.27B -7.12B -306B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-04-17 137.64 $ -0.66% 7,345,882
26-04-16 138.55 $ -0.87% 3,432,531
26-04-15 139.77 $ -0.48% 3,790,526
26-04-14 140.45 $ +1.02% 6,473,797
26-04-13 139.03 $ +0.03% 5,101,886
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
137.64USD
Average target price
158.36USD
Spread / Average Target
+15.05%

Quarterly revenue - Rate of surprise